Evidence method
Level · gp.fundamentals.debt_to_revenue
5757.76% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CRSP · Jun 30, 2026
CRISPR Therapeutics AG. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-330672General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
6.36% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-820.14% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
1041.37% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-1151.84% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
659.58% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
170.08% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History5 statesHistory building
Period transition
What moved in the state?
- Previous
- 40155.69%
- Current
- 5757.76%
- Delta
- -34397.93%
- Previous
- 34.57%
- Current
- 6.36%
- Delta
- -28.20%
- Previous
- -7468.93%
- Current
- -820.14%
- Delta
- 6648.79%
- Previous
- 68.55%
- Current
- 1041.37%
- Delta
- 972.81%
- Previous
- -8933.33%
- Current
- -1151.84%
- Delta
- 7781.49%
- Previous
- 4703.29%
- Current
- 659.58%
- Delta
- -4043.71%
- Previous
- 1119.62%
- Current
- 170.08%
- Delta
- -949.53%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Biological Products, (No Diagnostic Substances) peers →Has State · CRISPR Therapeutics AG →Transitioned To · CRSP Fundamental State →Transitioned To · CRSP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · CRSP CAPEX_INTENSITY_DECREASED →Transitioned To · CRSP CASH_GENERATION_INCREASED →Transitioned To · CRSP GROWTH_INCREASED →Transitioned To · CRSP PROFITABILITY_INCREASED →Transitioned To · CRSP R_AND_D_INTENSITY_DECREASED →Transitioned To · CRSP SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.